Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.55 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360301 | 1.00 | ECE1 (0.55) | ECE1GNPATENPEPNOD1PDCD1LG2 | |
| SCHEMBL31390152 | 0.95 | ECE1 (0.59) | ECE1GNPATENPEPNOD1PDCD1LG2 | |
| SCHEMBL30798028 | 0.93 | GNPAT (0.53) | ECE1GNPATENPEPNOD1MME | |
| SCHEMBL30798044 | 0.93 | GNPAT (0.53) | ECE1GNPATENPEPNOD1MME | |
| SCHEMBL11517272 | 0.92 | ECE1 (0.63) | ECE1NOD1PDCD1LG2CD274MME | |
| SCHEMBL30910815 | 0.92 | ECE1 (0.63) | ECE1NOD1PDCD1LG2CD274MME | |
| SCHEMBL5582285 | 0.92 | ECE1 (0.63) | ECE1NOD1PDCD1LG2CD274MME | |
| SCHEMBL2490629 | 0.92 | ECE1 (0.63) | ECE1NOD1PDCD1LG2CD274MME | |
| SCHEMBL21473104 | 0.92 | ECE1 (0.63) | ECE1NOD1PDCD1LG2CD274MME | |
| D-Alanine SCHEMBL9140010 | 0.90 | ECE1 (0.61) | ECE1NOD1PDCD1LG2CD274MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | PTK2, PCNA, CDK4 | ECE1 650/4885GNPAT 1874/4885ENPEP 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.